Iomeron (Iomeprol)

Iomeprol contains iodine atoms that strongly absorb X‑ray photons. After injection, it distributes in the extracellular space, raising the attenuation of X‑rays in blood and tissues. This creates a contrast difference between vessels or organs and surrounding structures, allowing more detailed visualization on radiographic, CT, and myelographic images.

The specific dose of Iomeron is determined by the prescribing physician based on the type of imaging study, patient weight, renal function, and clinical protocol. Dosage calculations are individualized and should follow the recommendations of the imaging department and the product’s prescribing information.

Iomeron is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used only if clearly needed. Limited data are available for breastfeeding; the decision to continue nursing should be made by the healthcare provider after weighing benefits and risks.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents, it provides comparable image quality while reducing the incidence of discomfort and adverse reactions. Choice of agent often depends on specific imaging requirements, patient risk factors, and institutional preferences.

Iomeron should be stored below 25 °C in its original container, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration. Handle with aseptic technique and avoid shaking the vial to maintain solution integrity.

Iomeron is administered as a sterile solution for injection via intra‑arterial, intravenous, or intrathecal routes, depending on the imaging procedure. The injection rate and volume are determined by the imaging protocol and patient characteristics. Administration should be performed by qualified healthcare professionals in a setting equipped for monitoring and emergency management.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and thyroid dysfunction due to iodine load. Prompt recognition and management of these events are essential, and patients at risk should be identified before administration.

Iomeron should be avoided in patients with a known hypersensitivity to iodinated contrast media, those with uncontrolled hyperthyroidism, and individuals with severe renal impairment where alternative imaging methods are feasible. Caution is also advised for patients on metformin with reduced kidney function, and for pregnant or breastfeeding women unless the diagnostic benefit outweighs potential risks.